G0544

GR 103691

≥98% (HPLC), solid

• 동의어(들): 4′-Acetyl-N-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]-[1,1′-biphenyl]-4-carboxamide
• 실험식(Hill 표기법): C₃₀H₃₅N₃O₃
• CAS Number: 162408-66-4
• Molecular Weight: 485.62
• MDL number: MFCD00936840
• UNSPSC 코드: 12352200
• PubChem Substance ID: 24724488
• NACRES: NA.77

속성

• Quality Level: 100
• 분석: ≥98% (HPLC)
• 양식: solid
• 색상: white
• solubility: DMSO: soluble >5 mg/mL at 60 °C
• 주관자: GlaxoSmithKline
• 저장 온도: 2-8°C
• SMILES string: COc1ccccc1N2CCN(CCCCNC(=O)c3ccc(cc3)-c4ccc(cc4)C(C)=O)CC2
• InChI: 1S/C30H35N3O3/c1-23(34)24-9-11-25(12-10-24)26-13-15-27(16-14-26)30(35)31-17-5-6-18-32-19-21-33(22-20-32)28-7-3-4-8-29(28)36-2/h3-4,7-16H,5-6,17-22H2,1-2H3,(H,31,35)
• InChI key: JARNORYOPMINDY-UHFFFAOYSA-N
• 유전자 정보: rat ... Htr1a(24473)

설명

애플리케이션

GR 103691 has been used as a D3 receptor antagonist to test its:

• inducing effect on prepulse inhibition (PPI)
• suppressive effect of motor behavior in rats
• inhibitory effect on chemotaxis in newly excysted juvenile C. sinensis (CsNEJs)

생화학적/생리학적 작용

D₃ dopamine receptor antagonist.

GR 103691 increases the monosynaptic “stretch” reflex (MSR) amplitude in mice by its potent D3 receptor antagonist functionality. It inhibits the PD 128,907 mediated γ-aminobutyric acid (GABA) release.

특징 및 장점

This compound is featured on the Dopamine Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

법적 정보

Sold for research purposes under agreement from Glaxo­Smith­Kline

안전성 정보

• Storage Class Code: 11 - Combustible Solids
• WGK: WGK 3
• Flash Point (°F): Not applicable
• Flash Point (°C): Not applicable
• 개인 보호 장비: Eyeshields, Gloves, type N95 (US)